Shots:BMS has entered into a definitive agreement to acquire Orbital, strengthening & diversifying its cell therapy portfolioAs per the deal, BMS will acquire Orbital, incl. its asset, OTX-201 & RNA platform, in an all-cash transaction of $1.5BOTX-201 is a preclinical circular RNA therapy encoding a CD19 CAR for in vivo expression delivered via…
Shots:Avant Technologies and Austrianova signed a joint venture and licensing agreement to form Klothonova, a 50/50 Nevada-based Joint Venture focused on developing cell-based therapies using encapsulated Klotho-producing cellsUnder the terms of the agreement, Klothonova will leverage Austrianova’s proprietary cell-encapsulation technology to develop and commercialize therapies for Alzheimer’s disease, heart disease, cancer, kidney disease,…
Shots: ADCs, cell therapies, and radioligand therapies are reshaping oncology, while biopharma companies focus on smarter trials, patient-first approaches, and faster access to bridge unmet needs in cancer care In 2024, the global oncology market was valued at $225.01B and is projected to reach $668.26B by 2034, reflecting a strong CAGR of 11.5% from 2025…
Shots:Xcell Biosciences entered into a strategic collaboration with ThermoFisher Scientific to advance the development of Treg and TIL cell therapies for autoimmune and solid tumor treatmentsThe joint research aims to develop methodologies for enhancing the efficacy of Tregs and TILs, while streamlining and scaling cell therapy manufacturing for improved accessibility and reproducibility across…
Shots:AstraZeneca to acquire EsoBiotec, which will operate as AstraZeneca’s subsidiary, while maintaining its operations in Belgium to advance cell therapy
As per the deal, AstraZeneca will acquire all outstanding equity of EsoBiotec on a cash & debt-free basis for ~$1B, incl. $425M upfront at closing & ~$575M in development & regulatory milestones; closing…
Shots:The US FDA has approved Encelto (revakinagene taroretcel-lwey) to treat macular telangiectasia type 2 (MacTel); commercially available in the US by Jun 2025
Approval was based on P-III trial data demonstrating reduced macular photoreceptor loss for ~24mos. post-implantation
Encelto (intravitreal implant) utilizes an encapsulated cell therapy tech to continuously deliver ciliary neurotrophic…
Shots:Carsten gave the details of the agreement with Neogene Therapeutics to bring cell therapies to patients with solid tumors through Neogene’s next-generation T-cell receptor therapies. He also talked about Neogene’s TCR discovery platformMark spoke about how this acquisition provides AstraZeneca with a unique opportunity to bring innovative science and leading experts in T-cell…
Chitkara University and DeepSynergy presents the Pharma Tech Conclave 2023. The conference will be held on 3rd Mar 2023 from 9:00 am to 5:00 pm IST at the Chitkara College of Pharmacy, Chitkara University, Chandigarh. The global pharmaceutical industry is undergoing transformational changes due to advancements in technological innovations that aim to fundamentally alter how patients…
INTRODUCTIONCerebral Palsy is a group of neurological disorders which affect motor and developmental skills. It causes disability in muscle tone, movement, balance, and posture. It is the most common motor disability in childhood with an estimated prevalence ranging from 1-4 per 1,000 live births. The incidence of CP is more in preterm or low…
In an interview with PharmaShots, Mark Frohlich, CEO at Indapta Therapeutics shared his views on the closing of $50M A financing and how it will advance its cell therapy drug developmentShots:The company closes $50M A financing, co-led by RA Capital Management, LP, Vertex Ventures HC, and Bayer AG with Mark Frohlich appointed as M.D.,…

